8月19日，Illumina盘中上涨5.16%，报198.835美元/股，成交额4351.73万美元。
消息面上，RBC Capital Markets近期发布报告指出，Illumina正在建立临床测序领域的增长动能，围绕公司的竞争担忧正在消退。RBC认为其临床测序收入可实现持续的中双位数增长，主要受肿瘤学检测量增长及定价逆风缓解驱动，并维持"跑赢大市"评级及230美元目标价。此外，公司Q2业绩超预期（调整后EPS 1.31美元超预期1.23美元，营收11.59亿美元超预期11.30亿美元），叠加SEC文件披露信贷协议中含最高5亿美元扩容选择权，均强化了市场信心。当日生命科学工具和服务板块整体走强，Tempus AI涨13.43%、Repligen涨5.78%，行业共振亦提供支撑。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.